Foghorn®-logo-color.jpg
Foghorn Therapeutics to Host Research & Development Day Webinar on June 15th
June 08, 2021 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Present in Two Upcoming Investor Conferences
May 26, 2021 08:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286
May 17, 2021 07:00 ET | Foghorn Therapeutics, Inc.
- First clinical candidate of a new class of therapeutics directly targeting the chromatin regulatory system - FHD-286 is a highly potent, selective, allosteric, oral, small molecule inhibitor of...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides Corporate Update
May 11, 2021 07:00 ET | Foghorn Therapeutics, Inc.
- Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma - Continued to advance broad therapeutic pipeline targeting the...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Appoints Ian Smith to its Board of Directors
April 28, 2021 07:00 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Provides Corporate Update
March 18, 2021 08:00 ET | Foghorn Therapeutics, Inc.
-  FHD-286 Phase 1 data anticipated as early as year-end 2021 -  FHD-609 IND submission on track for the second quarter 2021 -  Continued advancement of broad therapeutic pipeline targeting the...
Foghorn®-logo-color.jpg
UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021
March 11, 2021 17:11 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
March 11, 2021 16:01 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn®-logo-color.jpg
Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference
February 22, 2021 08:04 ET | Foghorn Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically...
Foghorn®-logo-color.jpg
Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
December 04, 2020 08:00 ET | Foghorn Therapeutics, Inc.
– Well positioned to advance broad pipeline with recent completion of IPO and Merck collaboration – On track to submit an IND for FHD-286 by year end 2020 and for FHD-609 during the first half of...